Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...

Novo Nordisk said the safety risks associated with compounded semaglutide are “significant”. The company outlaid key differences in formulations – such as pharmacies using synthetic ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

After the FDA declared a semaglutide shortage in 2022, pharmacies, telehealth companies and other health care providers have been able to manufacture copycat versions of Novo Nordisk‘s GLP-1 ...

Novo Nordisk has initiated two trials investigating the efficacy of semaglutide 7.2mg, STEP UP and STEP UP T2D. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group ...

A federal judge April 24 rejected a bid by compounding pharmacies to continue selling less expensive copies of semaglutide, Novo Nordisk's blockbuster drug sold under the brands Wegovy and Ozempic.

Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker's blockbuster weight loss drug Wegovy ...

The cost of compounded versions of semaglutide sold by online telehealth providers ranged from $150 to $280 for a month’s supply. “Novo Nordisk continues to advance solutions for patients that ...